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Dopamine (DA) is a key neurotransmitter modulating essential functions of the central
nervous system (CNS), like voluntary movement, reward, several cognitive functions
and goal-oriented behaviors. The factual relevance of DAergic transmission can be
well appreciated by considering that its dysfunction is recognized as a core alteration
in several devastating neurological and psychiatric disorders, including Parkinson’s
disease (PD) and associated movement disorders, as well as, schizophrenia, bipolar
disorder, attention deficit hyperactivity disorder (ADHD) and addiction. Here we present
an overview of the current knowledge on the involvement of DAergic receptors in
the regulation of key physiological brain activities, and the consequences of their
dysfunctions in brain disorders such as PD, schizophrenia and addiction.
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INTRODUCTION
Dopamine (DA) regulates important physiological brain’s functions, including locomotion, reward
and cognition, through different DAergic pathways, mainly originating in two mesencephalic
nuclei, the ventral tegmental area (VTA) and the substantia nigra pars compacta (SNpc; Dahlström
and Fuxe, 1964). DAergic neurons of the VTA project to limbic areas (nucleus accumbens
(NAc), hippocampus and amygdala) and cortical regions, thus composing the mesolimbic- and
mesocortical pathways, respectively, those of the SNpc constitute the nigrostriatal pathway mainly
projecting to the dorsal striatum.
According to a traditional belief, the different DAergic pathways mediate specific physiological
functions, with the nigrostriatal pathway involved in locomotion, and the mesolimbic/mesocortical
pathways implicated in reward and cognition. The evidence that Parkinson’s disease (PD), a
disorder mainly characterized by motor inabilities, is primarily due to a dysfunction of nigrostriatal
pathway, whereas neuropsychiatric disorders, like schizophrenia and addiction, involve a major
dysregulation of mesolimbic/mesocortical pathways, reinforces the hypothesis of a functional
segregation of DAergic pathways. Nowadays, however, this functional/physiopathological
subdivision is outdated, since a key role of the nigrostriatal pathway has been recognized
in cognitive functions (Haber, 2014), in reward, craving and aversion (Wise, 2009), and in
schizophrenia (Perez-Costas et al., 2010; Yoon et al., 2013; Weinstein et al., 2017).
DAergic RECEPTORS
Classification, Signaling and Regulatory Mechanisms
DA-induced effects are mediated by five G protein-coupled receptors (GPCR), classified
into two subclasses: the D1R-like and D2R-like receptor families. D1R-like receptors
(D1R and D5R) are coupled to Gs/olf proteins and stimulate adenylate cyclase (AC), with
production of cyclic adenosine monophosphate (cAMP) and activation of cAMP-dependent
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pathways, mainly including protein kinase A (PKA) and other
downstream signals. D1R modulate different ionic channels,
including voltage-activated Na+- (Nav), K+- (Kv) and Ca2+
(Cav) channels, Ca2+-activated K+- (KCa) and G-protein gated
inwardly rectifying K+ (GIRK) channels (Maurice et al., 2001;
Witkowski et al., 2008; Yang et al., 2013). D2R-like receptors
(D2R, D3R and D4R), by coupling to Gi/o proteins, induce
inhibition of AC and PKA-dependent pathways, as well as
activation of GIRK and closure of CaV (Missale et al., 1998)
(Figure 1).
D2R-like receptors genes generate variants. D2R exists in two
functional isoforms, D2 long (D2L) and D2 short (D2S; Giros
et al., 1989), whereas several D3R isoforms have been identified
(Giros et al., 1991). Multiple D4R variants are produced, mostly
having a domain repeated 2 (2R), 4 (4R) and 7 (7R) times (Van
Tol et al., 1992).
In addition to act as monomers, DAergic receptors constitute
dimeric and/or oligomeric complexes by association of different
subtypes either alone or with other GPCRs and ligand-gated
channels. Homodimers exist, like D1R-D2R, D2R-D4R,
D1R-D3R, D2R-D3R and D2R-D5R, as well as oligomeric
complexes containing DAergic receptors associated to the
adenosine A1 and A2, serotoninergic 5-HT2A, histaminergic
H3, glutamatergic mGlu5 and NMDA receptors (Perreault
et al., 2014). Dimeric/oligomeric complexes increase the
complexity of DA-mediated effects, since they may display
pharmacological/functional properties distinct from their
constituent receptors. Indeed, D1R-D2R are linked to Gq/11
proteins, thus modulating phospholipase C (PLC), which
produces inositol trisphosphate (IP3) and diacylglycerol (DAG)
to regulate intracellular Ca2+ (Lee et al., 2004) (Figure 1).
While the prevailing belief is that DAergic receptors
act through G proteins, they can also activate G proteins-
independent mechanisms. A role in the G protein-independent
signaling is played by arrestins, multifunctional adaptor proteins,
which bind DAergic receptors phosphorylated by GPCR
kinases (GRKs; Gainetdinov et al., 2004). Binding of arrestins
recruits several proteins, including Akt, GSK-3, MAPK, c-Src,
Mdm2 and N-ethylmaleimide-sensitive factor, thus greatly
enhancing DA-activated pathways (Beaulieu and Gainetdinov,
2011) (Figure 1).
GRKs also regulate DAergic receptors by mediating their
desensitization, since their phosphorylation elicits receptor’s
endocytosis. GRK2, GRK3, GRK4, GRK5 and GRK6 regulate
D1R and D2R (Tiberi et al., 1996; Ito et al., 1999; Watanabe et al.,
2002; Villar et al., 2009), whereas GRK4 controls D3R (Villar
et al., 2009).
Besides GRKs, the regulators of G protein signaling (RGS),
a group of GTPase-activating proteins acting on G protein,
negatively modulate DAergic receptors. Among RGS members,
RGS9–2 affects D2R (Cabrera-Vera et al., 2004), RGS4 modulates
D2R, D1R/D3R (Min et al., 2012) and D2R/A2A (Lerner and
Kreitzer, 2012), whereas R7 subgroup regulate D2R (Wani et al.,
2012).
PHYSIOLOGICAL FUNCTIONS OF DAergic
RECEPTORS
Control of Locomotion
The regulation of locomotion represents a well-characterized
function of DAergic receptors. Thus, DA in the dorsal striatum
modulates basal ganglia activity, by DAergic receptors mainly
FIGURE 1 | DAergic receptors signaling. Intracellular signaling pathways activated by D1- and D2-like receptors families. Gs/olf, Gi/o, Gq, Gβγ, G proteins; AC,
adenylyl cyclase; cAMP, 3′-5′-cyclic adenosine monophosphate; DARPP32, cyclic AMP-regulated phosphoprotein, 32 kDa; PPI, protein-phosphatase 1; ERK,
extracellular signal-regulated kinase protein kinase; PLC, phospholipase C; DAG, diacylglycerol; PKC, protein kinase C; IP3, inositol triphosphate; IP3R, inositol
triphosphate receptor; Ca2+, calcium; GIRK, G-protein gated inwardly rectifying K+ channels; Cav, voltage-activated Ca2+ channels; Nav, voltage-activated Na+
channels; Akt, thymoma viral proto-oncogene; GSK-3, Glycogen Synthase Kinase-3; MAPK, mitogen-activated protein kinase; Mdm2, mouse double minute
2 homolog; c-Src, proto-oncogene non-receptor tyrosine kinase; NSF, N-ethylmaleimide-sensitive factor.
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expressed on GABAergic medium spiny neurons (MSNs).
D1R and D2R principally display a segregated expression on
striatal MSNs (Gerfen and Surmeier, 2011). D1R-expressing
MSNs directly project to basal ganglia’s output nuclei, the
substantia nigra pars reticulata (SNpr) and the globus pallidus
internus (GPi; direct pathway). D2R-expressing MSNs project
to intermediate nuclei, the external globus pallidus (GPe) that
projects to the subthalamic nucleus (STN; indirect pathway).
The combined D1R/D2R activation regulates SNpr/GPi, which
control the excitation of the cortex via thalamus, thus
promoting/inhibiting locomotion. An opposite role of D1R-
and D2R-expressing neurons on movement has been recently
confirmed, since the stimulation of direct pathway facilitates
movement, while the activation of indirect pathway causes
hypokinesia (Kravitz et al., 2010). However, the evidence
that D1R/D2R is co-expressed in a small subgroup of MSNs
(Aizman et al., 2000) adds complexity to their roles in
movement.
Striatal DA effects are regulated by D2R autoreceptors,
localized presynaptically on DAergic terminals and
mesencephalic cells. Thus, D2R provide a negative feedback,
which by tuning neuronal firing and DA synthesis/release,
changes extracellular neurotransmitter level (Lacey et al., 1987;
Wolf and Roth, 1990). D3R, possibly as D2R/D3R, could also
act as inhibitory autoreceptors (De Mei et al., 2009; but see
Mercuri et al., 1997). Accordingly to an important role of D2R
in movement regulation, the constitutive deletion of all D2R
(Kelly et al., 1998) or D2L isoforms (Usiello et al., 2000; Wang
et al., 2000), as well as D2R deletion in adulthood (Bello et al.,
2016) impairs spontaneous and agonists-stimulated locomotion.
Interestingly, D2R on striatal cholinergic interneurons are
involved in catalexia induced by neuroleptics (D2 antagonists;
Kharkwal et al., 2016).
Specific DA-activated pathways, such as MEK/ERK, GSK3β
and mTOR, have been implicated in locomotion (Beaulieu et al.,
2005, 2007; Santini et al., 2007; Urs et al., 2011). Moreover,
GRK2 might regulate locomotion, since GRK2 KO mice display
altered movements associated with DAergic dysfunctions (Daigle
et al., 2014).
Therefore, a proper locomotion depends on MSNs D1R
and D2R function. While D2R and D3R autoreceptors mainly
regulate DA extracellular levels, D4R and D5R subtypes are
dispensable for DA-induced regulation of locomotion (Missale
et al., 1998).
Reward
The mesolimbic DAergic pathway plays a central role in the
processing of reward-related stimuli, which mainly increase
extracellular DA levels in the NAc (Di Chiara, 2002; Volkow
and Morales, 2015). Additionally, the nigrostriatal pathway also
mediates reward processing (Wise, 2009). DAergic transmission
contributes to the reward prediction signal, since DAergic
neuronal firing enhances following unexpected/novel rewards
and is inhibited if an expected reward does not materialize
(Schultz et al., 1997; Schultz, 2002).
D1R or D2R either are involved in reward induced by
natural stimuli (food, sex) or addictive drugs. In the NAc,
D1R and D2R are largely compartmentalized on MSNs of the
direct/indirect pathways, respectively (Gerfen et al., 1990). It
is believed that direct/indirect pathways have different roles in
reward, with the direct pathway mediating reward while the
indirect one encoding aversion (Hikida et al., 2010; Kravitz
et al., 2012). Thus, D1R-dependent stimulation of the direct
pathway causes reward, whereas D2R-induced inhibition of
indirect pathway opposes aversion and facilitates reward (Hikida
et al., 2013). Actually, accumbal D1R activation is sufficient to
produce reward (Caine et al., 2002), while a combined D1R/D2R
activation causes maximal reward (Steinberg et al., 2014).
However, the co-expression of D1R/D2R on a subpopulation
of MSNs (Perreault et al., 2012) renders the functions of
D1R/D2R on direct/indirect pathways more complex than is
usually thought.
D3R seem less involved in reward processing, but rather affect
addictive behaviors (Sokoloff and Le Foll, 2017). Contrasting
evidence exist about a role for D4R in reward (Di Ciano et al.,
2014), although genetic association studies found correlations
between D4R variants and addictive behaviors (Ptácˇek et al.,
2011). D5R are not involved in reward.
Regulation of Cognitive Functions
DA regulates essential cognitive functions through DAergic
receptors expressed in the prefrontal cortex (PFC), striatum
and hippocampus. However, the role of DA in cognition
appears rather complex and poorly elucidated at cellular level,
with DAergic receptors controlling ionic conductances and/or
synaptic plasticity on different neuronal populations (Floresco
and Magyar, 2006; Arnsten et al., 2015).
D1R-like receptors modulate several aspects of cognition.
D1R are highly expressed in PFC and striatum and moderately
in hippocampus, whereas D5R display a similar distribution
with lower levels. Thus, D1R family control working memory,
behavioral flexibility, decision-making and goal-directed
behaviors (Sawaguchi and Goldman-Rakic, 1991; Ragozzino,
2002; Floresco et al., 2006), as well as hippocampal-dependent
learning and memory (Packard and White, 1991; Bach et al.,
1999; El-Ghundi et al., 1999; Hansen and Manahan-Vaughan,
2014). D1R/D5R regulate cortical pyramidal neurons excitability
and recurrent excitations within neuronal networks (Seamans
and Yang, 2004) underlying executive functions, besides
controlling synaptic plasticity in striatum and hippocampus
(Calabresi et al., 1992b; Kerr and Wickens, 2001; Hansen and
Manahan-Vaughan, 2014).
D2R are highly expressed in striatum and hippocampus
and moderately in layer 5 of PFC and regulate behavioral
flexibility, goal-directed behaviors and decision-making, also
affecting working- and long-term memory (Ragozzino, 2002;
Floresco et al., 2006; Stelzel et al., 2013; Puig and Miller, 2015).
D2R-activated mechanisms modify cortical pyramidal neurons
excitability (Gulledge and Jaffe, 1998; Wang and Goldman-Rakic,
2004), and/or glutamatergic synaptic plasticity in striatum and
hippocampus (Calabresi et al., 1992b; Rocchetti et al., 2015;
Broussard et al., 2016).
Despite D3R are almost absent in PFC, they indirectly
modulate PFC-dependent cognitive functions, by inhibiting
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mesocortical DAergic activity and/or adjusting cortical Ach
levels (Loiseau and Millan, 2009; Gross and Drescher, 2012).
Thus, D3R inhibition improves attention, learning, memory and
executive functions (Nakajima et al., 2013), whereas striatal D3R
modulate behavioral flexibility (Groman et al., 2016).
D4R in PFC and hippocampus affect different cognitive tasks,
including inhibitory avoidance and object recognition memory
(Bernaerts and Tirelli, 2003; Powell et al., 2003; Woolley et al.,
2008), being also involved in attention and exploratory behavior
(Oak et al., 2000).
DAergic TRANSMISSION IN BRAIN
DISORDERS
Parkinson’s Disease (PD)
The progressive neurodegeneration of SNpc DAergic neurons
represents the core feature of PD, a neurological disorder
mainly characterized by severe motor inabilities. Indeed,
striatal DAergic denervation unbalances the activation rate of
direct/indirect pathways of basal ganglia, thus causing deficits
in movement initiations, rigidity and bradykinesia. In PD there
is a reorganization of DAergic receptors in basal ganglia (Albin
et al., 1989), being D2R expression increased in MSNs-indirect
pathway and D1R mRNAs reduced in MSNs-direct pathway
(Gerfen et al., 1990). Moreover, the SNpc neurons degeneration
leads to progressive loss of D2R on striatal presynaptic terminals.
Meanwhile, as a compensation, DAergic receptors become
supersensitive, possibly depending on a more effective G
protein-receptors coupling and/or an increased expression of
signaling proteins (Hornykiewicz, 2001; Napolitano et al., 2002).
Supersensitivity has been reported for striatal D1R and D2R,
particularly, in striato-pallidal/striato-nigral terminals (Corvol
et al., 2004; Guigoni et al., 2007; Prieto et al., 2011). Accordingly,
in PD animal models, the D1R-dependent regulation of
direct pathway enhances nigral GABA release (Mango et al.,
2014a).
Noteworthy, DAergic receptors supersensitivity could
represent the biological substrate underlying motor
abnormalities produced by prolonged treatments with the
DA precursor, L-DOPA. Its administration often causes motor
fluctuations and involuntary movements, namely L-DOPA-
induced dyskinesia (LID). Striatal D1R hyperactivation plays
a pivotal role in LID development (Cenci, 2007). Indeed, in
LID animal models, D1R-linked signaling is hyperactive, with
increased cAMP levels and higher phosphorylation of ERK1/2,
DARPP-32 and mTOR (Greengard et al., 1999; Picconi et al.,
2003; Aubert et al., 2005; Pavón et al., 2006; Santini et al., 2007).
Accordingly, strategies reducing D1R functions significantly
rescue motor abnormalities in LID models (Fiorentini et al.,
2016). Moreover, based on D1R-A1R expression on striatal
MSNs, the A1R modulation, by counteracting excessive
D1R signaling in PD, reduces L-DOPA-induced involuntary
movements (Mango et al., 2014b).
A dysfunctional RGS-dependent modulation of DAergic
receptors could contribute to motor disorders. Indeed,
RGS9–2 plays a role in the occurrence of motor anomalies
in LID, since RGS9–2 KO mice develop dyskinesia associated
with D2R dysfunctions, and RGS9–2 overexpression diminishes
L-DOPA-induced involuntary movements (Kovoor et al., 2005;
Gold et al., 2007).
Addiction
Addiction is a neuropsychiatric disorder characterized by
compulsive engagement in rewarding stimuli, despite adverse
consequences. It is considered dependent on complex neuronal
modifications induced by transcriptional/epigenetic mechanisms
following repeated exposure to reinforcing stimuli, based
on a psychobiological vulnerability (Volkow and Morales,
2015).
There are established associations between polymorphisms in
DAergic receptors genes and addiction, with genetic variants of
D1R, D2R, D3R and D4R linked to substance abuse, alcoholism,
bulimia nervosa and pathological gambling (Blum et al., 1995;
Comings et al., 1999; da Silva Lobo et al., 2007; Le Foll et al., 2009;
Ptácˇek et al., 2011).
Modifications in the mesolimbic/mesocortical DAergic
pathways represent core biological changes underlying
addictive behaviors. Synthetic/natural rewards increase
extracellular DA in limbic/cortical areas, besides producing
other long-term modifications, including a potentiation
of glutamatergic transmission in midbrain DAergic
nuclei, NAc, striatum and cortex (Volkow and Morales,
2015). Moreover, long-term changes in DAergic receptor
responsiveness possibly contribute to synaptic/neuronal
adaptations leading to psychostimulant-induced sensitization
and compulsion (Hyman et al., 2006). Actually, addictive drugs
downregulate D2R-like receptors, with a reduced expression
of striatal D2R and D3R in individuals addicted to cocaine,
methamphetamine, alcohol or heroin (Volkow et al., 1993, 1996,
2001).
Although modifications in D1R expression have not been
consistently demonstrated in addiction (Martinez et al., 2009),
D1R play a prominent role in the acquisition/maintenance
of self-administration behavior (Self, 2010). Thus,
pharmacological/genetic D1R inhibition reduces the sensitivity
to rewarding effects of psychostimulants and impairs cocaine
self-administration (Caine et al., 1995, 2007).
D2R in midbrain DA neurons are also involved in the
establishment of addictive behaviors, since D2R deletion
enhances food intake and sensitivity to locomotor/rewarding
properties of cocaine (Bello et al., 2011). Accordingly, drug intake
and impulsivity are inversely correlated with D2R availability in
SNpc/VTA (Buckholtz et al., 2010).
Modifications in RGS proteins affecting D2R may play a
role in addiction. Psychostimulants and D2R ligands exposure
alter RGS9-2 protein levels (Seeman et al., 2007), whereas
amphetamine self-administration increases RGS2/RGS4 mRNAs
expression in VTA/NAc, but reduces D2RS mRNAs levels in
VTA (Sun et al., 2015). Moreover, RGS9-2 deletion exacerbates
the rewarding/motor effects of psychostimulants, which are
instead counteracted by RGS9-2 overexpression (Rahman et al.,
2003; Traynor et al., 2009).
D3R do not directly control the reinforcing/psychomotor
effects of psychostimulants (Reavill et al., 2000; Caine et al.,
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2002), although a D3R deletion increases the sensitivity to
cocaine and amphetamine (Xu, 1998). D3R affect cue-induced
drug-seeking behaviors and relapse (Sokoloff and Le Foll, 2017),
thus D3R antagonists might represent potential therapeutics for
drug addiction.
D4R is considered a minor player in mediating
psychostimulants-induced reinforce (Costanza and Terry,
1998; Caine et al., 2002). D4R null mice appear more sensitive
to locomotor, but not rewarding, properties of addictive drugs
(Rubinstein et al., 1997; Thanos et al., 2010). Notwithstanding,
D4R represents a susceptibility gene for food/drug dependence
and pathological gambling (Comings et al., 1999; Ptácˇek et al.,
2011; Silveira et al., 2014). D4R are involved in relapse, thus their
inhibition has been proposed as a potential strategy for addiction
(Di Ciano et al., 2014).
Schizophrenia
The ‘‘DA theory’’ for a dysfunction of DAergic transmission
represents the first pathogenetic hypothesis of psychosis, being
postulated following the fortuitous discovery of antipsychotics,
acting as D2R antagonists. Actually, a hyperactivation of DAergic
mesencephalic nuclei associated to a DAergic hypofunction in
PFC have been demonstrated in schizophrenia (Howes and
Kapur, 2009; Perez-Costas et al., 2010; Yoon et al., 2013;
Weinstein et al., 2017). Besides DAergic dysfunctions, alterations
in glutamatergic transmission occur, with the ‘‘DA-Glutamate
hypothesis’’ representing the current pathogenetic theory for
schizophrenia (Laruelle et al., 2003).
Supersensitivity to DA, due to modified DAergic receptors
expression and/or functions, might contribute to schizophrenic
symptomatology (Seeman et al., 2005).
Evidence regarding modifications in D1R expression in
schizophrenia are contrasting, reporting either decreased (Okubo
et al., 1997; Friedman et al., 1999) or increased levels (Abi-
Dargham et al., 2002, 2012). However, hypostimulation of
cortical D1R likely contributes to cognitive/negative symptoms
(Abi-Dargham and Moore, 2003).
Some studies have highlighted altered D2R expression
(Frankle and Laruelle, 2002; Nikolaus et al., 2009), with a
specific increase in high-affinity D2R (D2RH) possibly mediating
DA supersensitivity underlying psychosis (Seeman, 2011).
Nevertheless, other evidence refutes modified D2R expression,
supporting the idea that the alterations detected in patients
represent a compensation to prolonged D2R antagonism with
antipsychotics (Calabresi et al., 1992a; Weinstein et al., 2017).
Dysfunctions in the D2R-β-arrestin interaction and in
β-arrestin-dependent modulation of Akt/GSK3 pathway
might be involved in schizophrenia (Beaulieu et al., 2009).
Actually, drugs affecting D2R/β-arrestin interaction demonstrate
antipsychotic effects in animal models of schizophrenia (Park
et al., 2016), revealing alternative therapeutic strategies,
downstream to D2R.
In light of their restricted localization in limbic areas,
D3R has been proposed as a valuable target for schizophrenia
treatment (Gurevich et al., 1997). D3R modulation could
improve cognitive/negative schizophrenic symptoms, without
producing extrapyramidal/motor effects as D2R antagonists
(Joyce and Millan, 2005). Actually, novel antipsychotics acting as
D3R partial agonists/antagonists, ameliorate cognitive/negative
schizophrenic symptoms (Leggio et al., 2016).
D4R also received interest as targets for schizophrenia’s
treatment, since the atypical antipsychotic, clozapine, mainly
acts as D4R antagonist. Moreover, increased cortical D4R levels
(Seeman et al., 1993) and D4R genetic variations have been
associated to schizophrenia (Hwu et al., 1998; Ptácˇek et al., 2011).
CONCLUSION
DAergic receptors play key roles in physiological brain
functioning, since they regulate locomotion, reward, cognitive
functions and goal-oriented behaviors. Modifications in
DAergic receptors expression and signaling occur in different
neurological and neuropsychiatric disorders. While modulators
of DAergic receptors already represent valuable drugs for the
symptomatic treatment of PD and schizophrenia, an in-depth
understanding of DAergic dysfunctions might lead to identify
novel biological targets to profoundly change the fate of
DA-related neurological and psychiatric conditions.
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